ROCKVILLE, Md., July 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to present at the 2nd Annual Cantor Fitzgerald Annual Healthcare Conference being held July 12-13 at Le Parker Meridien in New York, NY. Mr. Riley is scheduled to present on Wednesday, July 13, 2016 at 3:00 p.m. ET.
A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the web at http://wsw.com/webcast/cantor4/syn. After the presentation, a replay will be archived and accessible for 90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead candidates in Phase 2 development are: (1) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2nd-annual-cantor-fitzgerald-healthcare-conference-300294096.html
SOURCE Synthetic Biologics, Inc.
Released July 6, 2016